• Joan H Schiller, David Harrington, Chandra P Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H Johnson, and Eastern Cooperative Oncology Group.
• University of Wisconsin Hospital and Clinics, Madison, USA.
• N. Engl. J. Med. 2002 Jan 10; 346 (2): 929892-8.

BackgroundWe conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer.MethodsA total of 1207 patients with advanced non-small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel.ResultsThe response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1.ConclusionsNone of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.

27 keywords...

hide…